NASDAQ:ATHE

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

MELBOURNE, Australia, Dec. 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced it has been granted a licence by UniQuest, the commercialisation company of The University of Queensland (UQ), to novel zinc ionophore technology to ...

2020-12-22 05:42 5519

Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases

MELBOURNE, Australia, Nov. 16, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The new patent is the product of in-ho...

2020-11-17 01:09 1227

Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases

MELBOURNE, Australia, Nov. 16, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The new patent is the product of in-ho...

2020-11-16 21:42 2625

Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study

MELBOURNE, Australia and SAN FRANCISCO, Oct. 26, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study inthe United States. BioMUSE is a natur...

2020-10-27 10:03 3360

New data independently confirms and extends laboratory findings and expands safety profile of ATH434

MELBOURNE, Australia and SAN FRANCISCO, Aug. 3, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for present...

2020-08-04 09:33 7411

Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report

Highlights: * FDA provides guidance for ATH434 development pathway * Company compliant with minimum NASDAQ price * End of period cash balance of $9.2M bolstered by $1.5M following issue of shares on 2 July MELBOURNE, Australia and SAN FRANCISCO, July 30, 2020 /PRNewswire/ -- Alterity Therap...

2020-07-31 06:49 16775

Alterity Therapeutics meeting with US FDA provides development pathway for ATH434

MELBOURNE, Australia and SAN FRANCISCO, June 29, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce that it has received guidance from the US Food and Drug Administration (FDA) in relation to the development pathway for ATH434 ...

2020-06-30 11:14 5739

Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology

MELBOURNE, Austrilia and SAN FRANCISCO, May 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has presented data on ATH434 (formerly PBT434) for the treatment of Multiple System Atrophy at the American Academy of Neurology (AAN) virtual meeting....

2020-05-21 08:58 5963

Alterity Therapeutics Limited Releases Its Appendix 4C - Q3 FY20 Quarterly Cash Flow Report

Highlights: * European Commission designated Orphan Drug status for ATH434's treatment of Multiple System Atrophy in the European Union * Phase 2 preparatory work continues * Cash balance of $10.4M MELBOURNE, Australia and SAN FRANCISCO, April 30, 2020 /PRNewswire/ -- Alterity Therapeutics ...

2020-04-30 16:35 11071

Alterity Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement

MELBOURNE, Australia and SAN FRANCISCO, Feb. 7, 2020 /PRNewswire/ -- Alterity Therapeutics Limited (ASX:ATH, NASDAQ:ATHE) has received notification from the Listing Qualifications Department of NASDAQ advising the Company that it is currently non-compliant with NASDAQ's requirement that listed se...

2020-02-07 21:00 11415
123

Week's Top Stories